Jinwon Life Sciences Develops Microfluidic Electroporation System in Collaboration with Rutgers University, USA
[Asia Economy Reporter Jang Hyowon] Jinwon Life Sciences announced on the 15th that it has jointly developed a microfluidic electroporation system for single-cell intracellular nucleic acid delivery applicable to CAR-T therapeutics with the research team at Rutgers University College of Engineering.
Jinwon Life Sciences stated that the patent titled "High-performance feedback-controlled electroporation microdevice for effective molecular delivery into single cells" has already been registered in the United States, Europe, Japan, and India, and is currently under examination in Korea and other countries.
The microfluidic electroporation microdevice has achieved 95% gene delivery efficiency and 95% cell viability, and is currently optimizing flow conditions for high-capacity ex vivo intracellular gene delivery.
This system is ideally applicable to CAR-T therapeutics, and can deliver both DNA and mRNA genes. Existing CAR-T therapies use viral delivery systems, which raise safety concerns and have stringent cell maintenance conditions before viral application, limiting the lifespan of CAR-T cells; this system can improve these limitations.
Additionally, the system can be applied to treat rare diseases caused by genetic mutations by delivering normal genes in the form of DNA or RNA.
Park Younggeun, CEO of Jinwon Life Sciences, emphasized, "The microfluidic electroporation microdevice holds significant potential as a major breakthrough in CAR-T therapeutic development. By combining this system with our company's core competencies in DNA and RNA design and development, as well as the excellent pharmaceutical manufacturing capabilities of DNA and RNA at our subsidiary VGXI, we have achieved integration of key technologies for nucleic acid gene therapy development."
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "No Cure Available, Spread Accelerates... Already 105 Dead, American Infected"
- "If That's the Case, Why Not Just Buy Stocks?" ETFs in Name Only, Now 'Semiconductor-Heavy' and a Playground for Short-Term Traders
- "Reporters Who First Revealed Jo Jinwoong's Juvenile Offense History Cleared of Juvenile Act Violation"
- Instead of a National Assembly Profile, Now a 'Carpenter'... Ryu Hojung Says "I Couldn't Do a Body Profile Shoot Twice"
He added, "Based on this technology, our company has secured an opportunity to expand research and development into CAR-T therapeutics and other genetic disease treatments."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
